"use strict";(self.webpackChunkbuild_back_better_breakdown=self.webpackChunkbuild_back_better_breakdown||[]).push([[5024],{3905:function(e,n,a){a.d(n,{Zo:function(){return d},kt:function(){return l}});var t=a(7294);function r(e,n,a){return n in e?Object.defineProperty(e,n,{value:a,enumerable:!0,configurable:!0,writable:!0}):e[n]=a,e}function i(e,n){var a=Object.keys(e);if(Object.getOwnPropertySymbols){var t=Object.getOwnPropertySymbols(e);n&&(t=t.filter((function(n){return Object.getOwnPropertyDescriptor(e,n).enumerable}))),a.push.apply(a,t)}return a}function o(e){for(var n=1;n<arguments.length;n++){var a=null!=arguments[n]?arguments[n]:{};n%2?i(Object(a),!0).forEach((function(n){r(e,n,a[n])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(a)):i(Object(a)).forEach((function(n){Object.defineProperty(e,n,Object.getOwnPropertyDescriptor(a,n))}))}return e}function s(e,n){if(null==e)return{};var a,t,r=function(e,n){if(null==e)return{};var a,t,r={},i=Object.keys(e);for(t=0;t<i.length;t++)a=i[t],n.indexOf(a)>=0||(r[a]=e[a]);return r}(e,n);if(Object.getOwnPropertySymbols){var i=Object.getOwnPropertySymbols(e);for(t=0;t<i.length;t++)a=i[t],n.indexOf(a)>=0||Object.prototype.propertyIsEnumerable.call(e,a)&&(r[a]=e[a])}return r}var u=t.createContext({}),c=function(e){var n=t.useContext(u),a=n;return e&&(a="function"==typeof e?e(n):o(o({},n),e)),a},d=function(e){var n=c(e.components);return t.createElement(u.Provider,{value:n},e.children)},p={inlineCode:"code",wrapper:function(e){var n=e.children;return t.createElement(t.Fragment,{},n)}},h=t.forwardRef((function(e,n){var a=e.components,r=e.mdxType,i=e.originalType,u=e.parentName,d=s(e,["components","mdxType","originalType","parentName"]),h=c(a),l=r,f=h["".concat(u,".").concat(l)]||h[l]||p[l]||i;return a?t.createElement(f,o(o({ref:n},d),{},{components:a})):t.createElement(f,o({ref:n},d))}));function l(e,n){var a=arguments,r=n&&n.mdxType;if("string"==typeof e||r){var i=a.length,o=new Array(i);o[0]=h;var s={};for(var u in n)hasOwnProperty.call(n,u)&&(s[u]=n[u]);s.originalType=e,s.mdxType="string"==typeof e?e:r,o[1]=s;for(var c=2;c<i;c++)o[c]=a[c];return t.createElement.apply(null,o)}return t.createElement.apply(null,a)}h.displayName="MDXCreateElement"},9655:function(e,n,a){a.r(n),a.d(n,{frontMatter:function(){return s},contentTitle:function(){return u},metadata:function(){return c},toc:function(){return d},default:function(){return h}});var t=a(7462),r=a(3366),i=(a(7294),a(3905)),o=["components"],s={sidebar_position:2},u="Part 2 - Prescription Drug Inflation Rebates",c={unversionedId:"title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2",id:"title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2",title:"Part 2 - Prescription Drug Inflation Rebates",description:"SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS.",source:"@site/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2.md",sourceDirName:"title-13-committee-on-ways-and-means/title-13-subtitle-j",slug:"/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2",editUrl:"https://github.com/EdwardAngert/build-back-better-breakdown/tree/main/packages/create-docusaurus/templates/shared/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2.md",tags:[],version:"current",sidebarPosition:2,frontMatter:{sidebar_position:2},sidebar:"tutorialSidebar",previous:{title:"Part 1 - Lowering Prices Through Fair Drug Price Negotiation",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1"},next:{title:"Part 3 - Part D Improvements And Maximum Out-Of-Pocket Cap For Medicare Beneficiaries",permalink:"/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3"}},d=[{value:"SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS.",id:"sec-139101-medicare-part-b-rebate-by-manufacturers",children:[],level:2}],p={toc:d};function h(e){var n=e.components,a=(0,r.Z)(e,o);return(0,i.kt)("wrapper",(0,t.Z)({},p,a,{components:n,mdxType:"MDXLayout"}),(0,i.kt)("h1",{id:"part-2---prescription-drug-inflation-rebates"},"Part 2 - Prescription Drug Inflation Rebates"),(0,i.kt)("h2",{id:"sec-139101-medicare-part-b-rebate-by-manufacturers"},"SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) In General.--Section 1834 of the Social Security Act (42 U.S.C. \n")),(0,i.kt)("p",null,"1395m) is amended by adding at the end the following new subsection:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(z) Rebate by Manufacturers for Single Source Drugs With Prices \nIncreasing Faster Than Inflation.--\n            "),"(1) Requirements.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) Secretarial provision of information.--Not \n                later than 6 months after the end of each calendar \n                quarter beginning on or after July 1, 2023, the \n                Secretary shall, for each part B rebatable drug, report \n                to each manufacturer of such part B rebatable drug the \n                following for such calendar quarter:\n                            "),"(i) Information on the total number of\nunits of the billing and payment code described\nin subparagraph (A)(i) of paragraph (3) with\nrespect to such drug and calendar quarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) Information on the amount (if any) \n                        of the excess average sales price increase \n                        described in subparagraph (A)(ii) of such \n                        paragraph for such drug and calendar quarter.\n                            "),"(iii) The rebate amount specified under\nsuch paragraph for such part B rebatable drug\nand calendar quarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Manufacturer requirement.--For each calendar \n                quarter beginning on or after July 1, 2023, the \n                manufacturer of a part B rebatable drug shall, for such \n                drug, not later than 30 days after the date of receipt \n                from the Secretary of the information described in \n                subparagraph (A) for such calendar quarter, provide to \n                the Secretary a rebate that is equal to the amount \n                specified in paragraph (3) for such drug for such \n                calendar quarter.\n            "),"(2) Part b rebatable drug defined.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) In general.--In this subsection, the term \n                `part B rebatable drug' means a single source drug or \n                biological (as defined in subparagraph (D) of section \n                1847A(c)(6)), including a biosimilar biological product \n                (as defined in subparagraph (H) of such section), \n                payable (if such drug were furnished to an individual \n                enrolled under this part) under this part, except such \n                term shall not include such a drug or biological--\n                            "),"(i) if the average total allowed charges\nunder this part as determined by the Secretary\nfor a year per individual that uses such a drug\nor biological, as determined by the Secretary,\nare less than, subject to subparagraph (B),\n$100; or\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) that is a vaccine described in \n                        subparagraph (A) or (B) of section 1861(s)(10).\n                    "),"(B) Increase.--The dollar amount applied under\nsubparagraph (A)(i)--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) for 2024, shall be the dollar amount \n                        specified under such subparagraph for 2023, \n                        increased by the percentage increase in the \n                        consumer price index for all urban consumers \n                        (United States city average) for the 12-month \n                        period ending with June of the previous year; \n                        and\n                            "),"(ii) for a subsequent year, shall be the\ndollar amount specified in this clause (or\nclause (i)) for the previous year, increased by\nthe percentage increase in the consumer price\nindex for all urban consumers (United States\ncity average) for the 12-month period ending\nwith June of the previous year.\nAny dollar amount specified under this subparagraph\nthat is not a multiple of $10 shall be rounded to the\nnearest multiple of $10.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(3) Rebate amount.--\n                    "),"(A) In general.--For purposes of paragraph (1),\nthe amount specified in this paragraph for a part B\nrebatable drug assigned to a billing and payment code\nfor a calendar quarter is, subject to subparagraph (B)\nand paragraph (4), the amount equal to the product of--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) the total number of units, as \n                        described in section 1847A(c)(1)(B), with \n                        respect to such drug during the calendar \n                        quarter; and\n                            "),"(ii) the amount (if any) by which--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(I) the payment amount under \n                                subparagraph (B) or (C) of section \n                                1847A(b)(1), as applicable, for such \n                                part B rebatable drug during the \n                                calendar quarter; exceeds\n                                    "),"(II) the inflation-adjusted\npayment amount determined under\nsubparagraph (C) for such part B\nrebatable drug during the calendar\nquarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Excluded units.--For purposes of subparagraph \n                (A)(i), the Secretary shall exclude from the total \n                number of units with respect to a part B rebatable drug \n                and calendar quarter units of such part B rebatable \n                drug for which payment was made under a State plan \n                under title XIX (or waiver of such plan), as reported \n                by States under section 1927(b)(2)(A) for the most \n                recent rebate period.\n                    "),"(C) Determination of inflation-adjusted payment\namount.--The inflation-adjusted payment amount\ndetermined under this subparagraph for a part B\nrebatable drug for a calendar quarter is--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) the payment amount for the billing \n                        and payment code for such drug in the payment \n                        amount benchmark quarter (as defined in \n                        subparagraph (D)); increased by\n                            "),"(ii) the percentage by which the rebate\nperiod CPI-U (as defined in subparagraph (F))\nfor the calendar quarter exceeds the benchmark\nperiod CPI-U (as defined in subparagraph (E)).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(D) Payment amount benchmark quarter.--The term \n                `payment amount benchmark quarter' means the calendar \n                quarter beginning January 1, 2016.\n                    "),"(E) Benchmark period cpi-u.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"benchmark \n                period CPI-U' means the consumer price index for all \n                urban consumers (United States city average) for July \n                2015.\n                    ``(F) Rebate period cpi-u.--The term "),"rebate period\nCPI-U' means, with respect to a calendar quarter\ndescribed in subparagraph (C), the greater of the\nbenchmark period CPI-U and the consumer price index for\nall urban consumers (United States city average) for\nthe first month of the calendar quarter that is two\ncalendar quarters prior to such described calendar\nquarter.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(4) Special treatment of certain drugs and exemption.--\n                    "),"(A) Subsequently approved drugs.--Subject to\nsubparagraph (B), in the case of a part B rebatable\ndrug first approved or licensed by the Food and Drug\nAdministration after July 1, 2015, clause (i) of\nparagraph (3)(C) shall be applied as if the term\n",(0,i.kt)("inlineCode",{parentName:"p"},"payment amount benchmark quarter' were defined under \n                paragraph (3)(D) as the third full calendar quarter \n                after the day on which the drug was first marketed and \n                clause (ii) of paragraph (3)(C) shall be applied as if \n                the term "),"benchmark period CPI-U' were defined under\nparagraph (3)(E) as if the reference to ",(0,i.kt)("inlineCode",{parentName:"p"},"July 2015' \n                under such paragraph were a reference to "),"the first\nmonth of the first full calendar quarter after the day\non which the drug was first marketed'.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(B) Timeline for provision of rebates for \n                subsequently approved drugs.--In the case of a part B \n                rebatable drug first approved or licensed by the Food \n                and Drug Administration after July 1, 2015, paragraph \n                (1)(B) shall be applied as if the reference to `July 1, \n                2023' under such paragraph were a reference to the \n                later of the 6th full calendar quarter after the day on \n                which the drug was first marketed or July 1, 2023.\n                    "),"(C) Exemption for shortages.--The Secretary may\nreduce or waive the rebate amount under paragraph\n(1)(B) with respect to a part B rebatable drug that is\ndescribed as currently in shortage on the shortage list\nin effect under section 506E of the Federal Food, Drug,\nand Cosmetic Act or in the case of other exigent\ncircumstances, as determined by the Secretary.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(D) Selected drugs.--In the case of a part B \n                rebatable drug that is a selected drug (as defined in \n                section 1192(c)) for a price applicability period (as \n                defined in section 1191(b)(2))--\n                            "),"(i) for calendar quarters during such\nperiod for which a maximum fair price (as\ndefined in section 1191(c)(2)) for such drug\nhas been determined and is applied under part E\nof title XI, the rebate amount under paragraph\n(1)(B) shall be waived; and\n",(0,i.kt)("inlineCode",{parentName:"p"},"(ii) in the case such drug is determined \n                        (pursuant to such section 1192(c)) to no longer \n                        be a selected drug, for each applicable year \n                        beginning after the price applicability period \n                        with respect to such drug, clause (i) of \n                        paragraph (3)(C) shall be applied as if the \n                        term `payment amount benchmark quarter' were \n                        defined under paragraph (3)(D) as the calendar \n                        quarter beginning January 1 of the last year \n                        beginning during such price applicability \n                        period with respect to such selected drug and \n                        clause (ii) of paragraph (3)(C) shall be \n                        applied as if the term `benchmark period CPI-U' \n                        were defined under paragraph (3)(E) as if the \n                        reference to `July 2015' under such paragraph \n                        were a reference to the July of the year \n                        preceding such last year.\n            "),"(5) Application to beneficiary coinsurance.--In the case\nof a part B rebatable drug, if the payment amount under this\npart for a quarter exceeds the inflation adjusted payment for\nsuch quarter--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) in computing the amount of any coinsurance \n                applicable under this part to an individual to whom \n                such drug is furnished, the computation of such \n                coinsurance shall be based on the inflation-adjusted \n                payment amount determined under paragraph (3)(C) for \n                such part B rebatable drug; and\n                    "),"(B) the amount of such coinsurance is equal to 20\npercent of such inflation-adjusted payment amount so\ndetermined.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(6) Rebate deposits.--Amounts paid as rebates under \n        paragraph (1)(B) shall be deposited into the Federal \n        Supplementary Medical Insurance Trust Fund established under \n        section 1841.\n            "),"(7) Civil money penalty.--If a manufacturer of a part B\nrebatable drug has failed to comply with the requirements under\nparagraph (1)(B) for such drug for a calendar quarter, the\nmanufacturer shall be subject to, in accordance with a process\nestablished by the Secretary pursuant to regulations, a civil\nmoney penalty in an amount equal to at least 125 percent of the\namount specified in paragraph (3) for such drug for such\ncalendar quarter. The provisions of section 1128A (other than\nsubsections (a) (with respect to amounts of penalties or\nadditional assessments) and (b)) shall apply to a civil money\npenalty under this paragraph in the same manner as such\nprovisions apply to a penalty or proceeding under section\n1128A(a).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(8) Application to multiple source drugs.--The Secretary \n        may, pursuant to rulemaking, apply the provisions of this \n        subsection to multiple source drugs (as defined in section \n        1847A(c)(6)(C)), including, for purposes of determining the \n        rebate amount under paragraph (3), by calculating manufacturer-\n        specific average sales prices for the benchmark period and the \n        rebate period.''.\n    (b) Amounts Payable; Cost-Sharing.--Section 1833 of the Social \nSecurity Act (42 U.S.C. 1395l) is amended--\n            (1) in subsection (a)--\n                    (A) in paragraph (1)--\n                            (i) in subparagraph (G), by inserting "),",\nsubject to subsection (i)(9),'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"the \n                        amounts paid'';\n                            (ii) in subparagraph (S), by striking \n                        "),"with respect to'' and inserting ",(0,i.kt)("inlineCode",{parentName:"p"},"subject to \n                        subparagraph (DD), with respect to'';\n                            (iii) by striking "),"and (DD)'' and\ninserting ",(0,i.kt)("inlineCode",{parentName:"p"},"(EE)''; and\n                            (iv) by inserting before the semicolon at \n                        the end the following: "),", and (EE) with\nrespect to a part B rebatable drug (as defined\nin paragraph (2) of section 1834(z)) for which\nthe payment amount for a calendar quarter under\nparagraph (3)(A)(ii)(I) of such section for\nsuch quarter exceeds the inflation-adjusted\npayment under paragraph (3)(A)(ii)(II) of such\nsection for such quarter, the amounts paid\nshall be the difference between (i) the payment\namount under paragraph (3)(A)(ii)(I) of such\nsection for such drug, and (ii) 20 percent of\nthe inflation-adjusted payment amount under\nparagraph (3)(A)(ii)(II) of such section for\nsuch drug''; and\n(B) by adding at the end of the flush left matter\nfollowing paragraph (9), the following:\n",(0,i.kt)("inlineCode",{parentName:"p"},"For purposes of applying paragraph (1)(EE), subsections (i)(9) and \n(t)(8)(F), and section 1834(z)(5), the Secretary shall make such \nestimates and use such data as the Secretary determines appropriate, \nand may do so by program instruction or otherwise.'';\n            (2) in subsection (i), by adding at the end the following \n        new paragraph:\n    "),"(9) In the case of a part B rebatable drug (as defined in\nparagraph (2) of section 1834(z)) for which payment under this\nsubsection is not packaged into a payment for a covered OPD service (as\ndefined in subsection (t)(1)(B)) (or group of services) furnished on or\nafter July 1, 2023, under the system under this subsection, in lieu of\ncalculation of coinsurance and the amount of payment otherwise\napplicable under this subsection, the provisions of section 1834(z)(5),\nparagraph (1)(EE) of subsection (a), and the flush left matter\nfollowing paragraph (9) of subsection (a), shall, as determined\nappropriate by the Secretary, apply under this subsection in the same\nmanner as such provisions of section 1834(z)(5) and subsection (a)\napply under such section and subsection.''; and\n(3) in subsection (t)(8), by adding at the end the\nfollowing new subparagraph:\n",(0,i.kt)("inlineCode",{parentName:"p"},"(F) Part b rebatable drugs.--In the case of a \n                part B rebatable drug (as defined in paragraph (2) of \n                section 1834(z)) for which payment under this part is \n                not packaged into a payment for a service furnished on \n                or after July 1, 2023, under the system under this \n                subsection, in lieu of calculation of coinsurance and \n                the amount of payment otherwise applicable under this \n                subsection, the provisions of section 1834(z)(5), \n                paragraph (1)(EE) of subsection (a), and the flush left \n                matter following paragraph (9) of subsection (a), \n                shall, as determined appropriate by the Secretary, \n                apply under this subsection in the same manner as such \n                provisions of section 1834(z)(5) and subsection (a) \n                apply under such section and subsection.''.\n    (c) Conforming Amendments.--\n            (1) To part b asp calculation.--Section 1847A(c)(3) of the \n        Social Security Act (42 U.S.C. 1395w-3a(c)(3)) is amended by \n        inserting "),"or section 1834(z)'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"section 1927''.\n            (2) Excluding parts b drug inflation rebate from best \n        price.--Section 1927(c)(1)(C)(ii)(I) of the Social Security Act \n        (42 U.S.C. 1396r-8(c)(1)(C)(ii)(I)) is amended by inserting \n        "),"or section 1834(z)'' after ",(0,i.kt)("inlineCode",{parentName:"p"},"this section''.\n            (3) Coordination with medicaid rebate information \n        disclosure.--Section 1927(b)(3)(D)(i) of the Social Security \n        Act (42 U.S.C. 1396r-8(b)(3)(D)(i)) is amended by striking "),"or\nto carry out section 1847B'' and inserting ``to carry out\nsection 1847B or section 1834(z)''."),(0,i.kt)("p",null,"SEC. 139102. MEDICARE PART D REBATE BY MANUFACTURERS."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"(a) In General.--Part D of title XVIII of the Social Security Act \n")),(0,i.kt)("p",null,"is amended by inserting after section 1860D-14A (42 U.S.C. 1395w-114a)\nthe following new section:"),(0,i.kt)("p",null,"``SEC. 1860D-14B. MANUFACTURER REBATE FOR CERTAIN DRUGS WITH PRICES\nINCREASING FASTER THAN INFLATION."),(0,i.kt)("pre",null,(0,i.kt)("code",{parentName:"pre"},"``(a) Requirements.--\n        ``(1) Secretarial provision of information.--Not later than \n    9 months after the end of each applicable year (as defined in \n    subsection (g)(7)), the Secretary shall, for each part D \n    rebatable drug, report to each manufacturer of such part D \n    rebatable drug the following for such year:\n                ``(A) Information on the amount (if any) of the \n            excess average manufacturer price increase described in \n            subsection (b)(1)(B) for each dosage form and strength \n            with respect to such drug and year.\n                ``(B) The rebate amount specified under subsection \n            (b) for each dosage form and strength with respect to \n            such drug and year.\n        ``(2) Manufacturer requirements.--For each applicable year, \n    the manufacturer of a part D rebatable drug, for each dosage \n    form and strength with respect to such drug, not later than 30 \n    days after the date of receipt from the Secretary of the \n    information described in paragraph (1) for such year, shall \n    provide to the Secretary a rebate that is equal to the amount \n    specified in subsection (b) for such dosage form and strength \n    with respect to such drug for such year.\n``(b) Rebate Amount.--\n        ``(1) In general.--\n                ``(A) Calculation.--For purposes of this section, \n            the amount specified in this subsection for a dosage \n            form and strength with respect to a part D rebatable \n            drug and applicable year is, subject to subparagraph \n            (B) of this paragraph and subparagraphs (B) and (C) of \n            paragraph (5), the amount equal to the product of--\n                        ``(i) the total number of units that are \n                    used to calculate the average manufacturer \n                    price of such dosage form and strength with \n                    respect to such part D rebatable drug, as \n                    reported by the manufacturer of such drug under \n                    section 1927 for each recent rebate period \n                    under such section, with respect to such year, \n                    under such section for which such information \n                    is available; and\n                        ``(ii) the amount (if any) by which--\n                                ``(I) the annual manufacturer price \n                            (as determined in paragraph (2)) paid \n                            for such dosage form and strength with \n                            respect to such part D rebatable drug \n                            for the year; exceeds\n                                ``(II) the inflation-adjusted \n                            payment amount determined under \n                            paragraph (3) for such dosage form and \n                            strength with respect to such part D \n                            rebatable drug for the year.\n                ``(B) Excluded units.--For purposes of subparagraph \n            (A)(i), the Secretary shall exclude from the total \n            number of units for a dosage form and strength with \n            respect to a part D rebatable drug and the most recent \n            rebate period under section 1927, with respect to an \n            applicable year, for which such information is \n            available, units of each dosage form and strength of \n            such part D rebatable drug, for which payment was made \n            under a State plan under title XIX (or waiver of such \n            plan), as reported by States under section \n            1927(b)(2)(A) for such rebate period.\n        ``(2) Determination of annual manufacturer price.--The \n    annual manufacturer price determined under this paragraph for a \n    dosage form and strength, with respect to a part D rebatable \n    drug and an applicable year, is the sum of the products of--\n                ``(A) the average manufacturer price (as defined in \n            subsection (g)(6)) of such dosage form and strength, as \n            calculated for a unit of such drug, with respect to \n            each of the calendar quarters of such year; and\n                ``(B) the ratio of--\n                        ``(i) the total number of units of such \n                    dosage form and strength reported for the \n                    purpose of calculating average manufacturer \n                    price under section 1927 during each such \n                    calendar quarter of such year; to\n                        ``(ii) the total number of units of such \n                    dosage form and strength reported for the \n                    purpose of calculating average manufacturer \n                    price under section 1927 during such year, as \n                    determined by the Secretary.\n        ``(3) Determination of inflation-adjusted payment amount.--\n    The inflation-adjusted payment amount determined under this \n    paragraph for a dosage form and strength with respect to a part \n    D rebatable drug for an applicable year, subject to \n    subparagraphs (A) and (D) of paragraph (5), is--\n                ``(A) the benchmark year manufacturer price \n            determined under paragraph (4) for such dosage form and \n            strength with respect to such drug and year; increased \n            by\n                ``(B) the percentage by which the applicable year \n            CPI-U (as defined in subsection (g)(5)) for the year \n            exceeds the benchmark period CPI-U (as defined in \n            subsection (g)(4)).\n        ``(4) Determination of benchmark year manufacturer price.--\n    The benchmark year manufacturer price determined under this \n    paragraph for a dosage form and strength, with respect to a \n    part D rebatable drug and an applicable year, is the sum of the \n    products of--\n                ``(A) the average manufacturer price (as defined in \n            subsection (g)(6)) of such dosage form and strength, as \n            calculated for a unit of such drug, with respect to \n            each of the calendar quarters of the payment amount \n            benchmark year (as defined in subsection (g)(3)); and\n                ``(B) the ratio of--\n                        ``(i) the total number of units of such \n                    dosage form and strength dispensed during each \n                    such calendar quarter of such payment amount \n                    benchmark year; to\n                        ``(ii) the total number of units of such \n                    dosage form and strength dispensed during such \n                    payment amount benchmark year.\n        ``(5) Special treatment of certain drugs and exemption.--\n                ``(A) Subsequently approved drugs.--In the case of \n            a part D rebatable drug first approved or licensed by \n            the Food and Drug Administration after January 1, 2016, \n            subparagraphs (A) and (B) of paragraph (4) shall be \n            applied as if the term `payment amount benchmark year' \n            were defined under subsection (g)(3) as the first \n            calendar year beginning after the day on which the drug \n            was first marketed by any manufacturer and subparagraph \n            (B) of paragraph (3) shall be applied as if the term \n            `benchmark period CPI-U' were defined under subsection \n            (g)(4) as if the reference to `January 2016' under such \n            subsection were a reference to `January of the first \n            year beginning after the date on which the drug was \n            first marketed by any manufacturer'.\n                ``(B) Exemption for shortages.--The Secretary may \n            reduce or waive the rebate under paragraph (1) with \n            respect to a part D rebatable drug that is described as \n            currently in shortage on the shortage list in effect \n            under section 506E of the Federal Food, Drug, and \n            Cosmetic Act or in the case of other exigent \n            circumstances, as determined by the Secretary.\n                ``(C) Treatment of new formulations.--\n                        ``(i) In general.--In the case of a part D \n                    rebatable drug that is a line extension of a \n                    part D rebatable drug that is an oral solid \n                    dosage form, the Secretary shall establish a \n                    formula for determining the amount specified in \n                    this subsection with respect to such part D \n                    rebatable drug and an applicable year with \n                    consideration of the original part D rebatable \n                    drug.\n                        ``(ii) Line extension defined.--In this \n                    subparagraph, the term `line extension' means, \n                    with respect to a part D rebatable drug, a new \n                    formulation of the drug, such as an extended \n                    release formulation, but does not include an \n                    abuse-deterrent formulation of the drug (as \n                    determined by the Secretary), regardless of \n                    whether such abuse-deterrent formulation is an \n                    extended release formulation.\n                ``(D) Selected drugs.--In the case of a part D \n            rebatable drug that is a selected drug (as defined in \n            section 1192(c)) for a price applicability period (as \n            defined in section 1191(b)(2))--\n                        ``(i) for plan years during such period for \n                    which a maximum fair price (as defined in \n                    section 1191(c)(2)) for such drug has been \n                    determined and is applied under part E of title \n                    XI, the rebate under subsection (a)(1)(B) shall \n                    be waived; and\n                        ``(ii) in the case such drug is determined \n                    (pursuant to such section 1192(c)) to no longer \n                    be a selected drug, for each applicable year \n                    beginning after the price applicability period \n                    with respect to such drug, subparagraphs (A) \n                    and (B) of paragraph (4) shall be applied as if \n                    the term `payment amount benchmark year' were \n                    defined under subsection (g)(3) as the last \n                    year beginning during such price applicability \n                    period with respect to such selected drug and \n                    subparagraph (B) of paragraph (3) shall be \n                    applied as if the term `benchmark period CPI-U' \n                    were defined under subsection (g)(4) as if the \n                    reference to `January 2016' under such \n                    subsection were a reference to January of the \n                    last year beginning during such price \n                    applicability period with respect to such drug.\n``(c) Rebate Deposits.--Amounts paid as rebates under subsection \n")),(0,i.kt)("p",null,"(b) shall be deposited into the Medicare Prescription Drug Account in\nthe Federal Supplementary Medical Insurance Trust Fund established\nunder section 1841.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(d) Information.--For purposes of carrying out this section, the \nSecretary shall use information submitted by manufacturers under \nsection 1927(b)(3) and information submitted by States under section \n1927(b)(2)(A).\n    "),"(e) Civil Money Penalty.--If a manufacturer of a part D rebatable\ndrug has failed to comply with the requirement under subsection\n(a)(1)(B) with respect to such drug for an applicable year, the\nmanufacturer shall be subject to, in accordance with a process\nestablished by the Secretary pursuant to regulations, a civil money\npenalty in an amount equal to 125 percent of the amount specified in\nsubsection (b) for such drug for such year. The provisions of section\n1128A (other than subsections (a) (with respect to amounts of penalties\nor additional assessments) and (b)) shall apply to a civil money\npenalty under this subsection in the same manner as such provisions\napply to a penalty or proceeding under section 1128A(a).\n",(0,i.kt)("inlineCode",{parentName:"p"},"(f) Judicial Review.--There shall be no judicial review of the \nfollowing:\n            "),"(1) The determination of units under this section.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) The determination of whether a drug is a part D \n        rebatable drug under this section.\n            "),"(3) The calculation of the rebate amount under this\nsection.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(g) Definitions.--In this section:\n            "),"(1) Part d rebatable drug defined.--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(A) In general.--The term `part D rebatable drug' \n                means a drug or biological that would (without \n                application of this section) be a covered part D drug, \n                except such term shall, with respect to an applicable \n                year, not include such a drug or biological if the \n                average annual total cost under this part for such year \n                per individual who uses such a drug or biological, as \n                determined by the Secretary, is less than, subject to \n                subparagraph (B), $100, as determined by the Secretary \n                using the most recent data available or, if data is not \n                available, as estimated by the Secretary.\n                    "),"(B) Increase.--The dollar amount applied under\nsubparagraph (A)--\n",(0,i.kt)("inlineCode",{parentName:"p"},"(i) for 2024, shall be the dollar amount \n                        specified under such subparagraph for 2023, \n                        increased by the percentage increase in the \n                        consumer price index for all urban consumers \n                        (United States city average) for the 12-month \n                        period beginning with January of 2023; and\n                            "),"(ii) for a subsequent year, shall be the\ndollar amount specified in this subparagraph\nfor the previous year, increased by the\npercentage increase in the consumer price index\nfor all urban consumers (United States city\naverage) for the 12-month period beginning with\nJanuary of the previous year.\nAny dollar amount specified under this subparagraph\nthat is not a multiple of $10 shall be rounded to the\nnearest multiple of $10.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(2) Unit defined.--The term `unit' means, with respect to \n        a part D rebatable drug, the lowest identifiable quantity (such \n        as a capsule or tablet, milligram of molecules, or grams) of \n        the part D rebatable drug, including data reported under \n        section 1927.\n            "),"(3) Payment amount benchmark year.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"payment \n        amount benchmark year' means the year beginning January 1, \n        2016.\n            ``(4) Benchmark period cpi-u.--The term "),"benchmark period\nCPI-U' means the consumer price index for all urban consumers\n(United States city average) for January 2016.\n",(0,i.kt)("inlineCode",{parentName:"p"},"(5) Applicable year cpi-u.--The term `applicable year \n        CPI-U' means, with respect to an applicable year, the consumer \n        price index for all urban consumers (United States city \n        average) for January of such year.\n            "),"(6) Average manufacturer price.--The term ",(0,i.kt)("inlineCode",{parentName:"p"},"average \n        manufacturer price' has the meaning, with respect to a part D \n        rebatable drug of a manufacturer, given such term in section \n        1927(k)(1), with respect to a covered outpatient drug of a \n        manufacturer for a rebate period under section 1927.\n            ``(7) Applicable year.--The term "),"applicable year' means a\nyear beginning with 2023.''.\n(b) Conforming Amendments.--\n(1) To part b asp calculation.--Section 1847A(c)(3) of the\nSocial Security Act (42 U.S.C. 1395w-3a(c)(3)), as amended by\nsection 139101(c)(1), is further amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"section \n        1927 or section 1834(z)'' and inserting "),"section 1927, section\n1834(z), or section 1860D-14B''.\n(2) Excluding part d drug inflation rebate from best\nprice.--Section 1927(c)(1)(C)(ii)(I) of the Social Security Act\n(42 U.S.C. 1396r-8(c)(1)(C)(ii)(I)), as amended by section\n139101(c)(2), is further amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"or section \n        1834(z)'' and inserting "),", section 1834(z), or section 1860D-\n14B''.\n(3) Coordination with medicaid rebate information\ndisclosure.--Section 1927(b)(3)(D)(i) of the Social Security\nAct (42 U.S.C. 1396r-8(b)(3)(D)(i)), as amended by section\n139101(c)(3), is further amended by striking ",(0,i.kt)("inlineCode",{parentName:"p"},"or section \n        1834(z)'' and inserting "),", section 1834(z), or section 1860D-\n14B''."))}h.isMDXComponent=!0}}]);